Clinical Research Directory

Inclusion Criteria: 1. Laboratory personnel, epidemiologists, EISOs, veterinary students, interns, and other first responders at CDC; other CDC employees; and healthy volunteer adults. Persons who contact the study coordinator will be assessed for possible occupational exposure to rabies using the risk assessment form (appendix E). The volunteers reporting occupational exposure will be selected to enter the study. 2. Male or nonpregnant females (as indicated by a negative urine pregnancy test prior to first dose of vaccine), aged 18 years and older. 3. Women of childbearing potential who are at risk of becoming pregnant must agree to practice adequate contraception (i.e., barrier method, abstinence, or licensed hormonal methods) for the entire study period. 4. Be in good health, as determined by vital signs (pulse, blood pressure, oral temperature), medical history, and a targeted physical examination based on medical history. 5. Able to understand and comply with planned study procedures. 6. Provide informed consent prior to any study procedures and be available for all study visits. 7. Have health insurance. Exclusion Criteria: 1. Have a known allergy to PCECV. 2. Have a known allergy or sensitivity to eggs or latex (in the stopper). 3. Have a positive urine pregnancy test prior to first vaccine dose (female of childbearing potential age). 4. Are immunosuppressed as a result of an underlying illness or treatment. 5. Have active neoplastic disease or a history of any hematologic malignancy. 6. Are using oral or parenteral steroids, high-dose inhaled steroids (\>800 μg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs. 7. Have a history of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study. 8. Have an acute illness that is accompanied by an oral temperature greater than 100.4°F, within 1 week of vaccination. 9. Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to enrollment in this study, or expects to receive an experimental agent during the 1st month of the study period. 10. Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. 11. He/she is a CDC worker under direct supervision of any of the primary study investigators (Dr. Sergio Recuenco, and Dr. Eli Warnock).